赛通姆治疗
CTMX
2.28
-0.13
-5.39%
赛通姆治疗
US · CTMX
#3678 按市值排名
上市于 2015
2.28
-0.13
-5.39%
实时 - 追踪5344个代码 - 心跳于197秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 105.18% +0.09pp
- 机构数量
- 201
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund49.73%
Hedge Fund28.30%
VC/PE Fund18.14%
Public Company8.31%
Individual/Insider0.57%
Government Pension Fund0.26%
Insurance Company0.18%
Private Company0.16%
主要股东 截至 2026-06-30
FMR
15.01% · 32.71M 股
Kynam Capital Management, LP
9.96% · 21.70M 股
BlackRock
8.06% · 17.56M 股
Longitude Capital Management Co., LLC
7.02% · 15.29M 股
Bank of America Corporation
6.92% · 15.08M 股
State Street Global Advisors
5.39% · 11.75M 股
Perceptive Advisors LLC
4.79% · 10.44M 股
Vanguard Capital Management, LLC
4.49% · 9.79M 股
Point72 Asset Management, L.P.
3.58% · 7.81M 股
Wellington Management Group
2.37% · 5.17M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 40次买入 · 10次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Sean McCarthy | Chairperson & CEO | 0.37% |
| Marcia Belvin | Senior VP & Chief Scientific Officer | 0.08% |
| Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | 0.06% |
| Lloyd Rowland | Senior VP, General Counsel, Chief Compliance Officer & Secretary | 0.04% |
| Yu-Waye Chu | Chief Medical Officer | 0.02% |
| Elaine Jones | Independent Director | 0.00% |
| Mani Mohindru | Independent Director | -- |
| James Meyers | Independent Director | -- |
| Matthew Young | Lead Independent Director | -- |
| Halley Gilbert | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-02 | Alejandra Carvajal | Chief Legal Officer | Other Acquisition | +100,000 | -- |
| 2026-08-02 | Alejandra Carvajal | Chief Legal Officer | Other Derivative Acquisition | +450,000 | $3.17 |
| 2026-07-23 | Charles Fuchs | Former Independent Director | Other Derivative Acquisition | +118,000 | $3.24 |
| 2026-06-16 | Elaine Jones | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Mani Mohindru | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | James Meyers | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Matthew Young | Lead Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Halley Gilbert | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Alan Ashworth | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Zhen Su | Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-14 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -1,624 | $3.05 |
| 2026-03-16 | Sean McCarthy | Chairperson & CEO | Open Market Disposition | -118,969 | $6.42 |
| 2026-03-16 | Yu-Waye Chu | Chief Medical Officer | Open Market Disposition | -21,279 | $6.42 |
| 2026-03-16 | Marcia Belvin | Senior VP & Chief Scientific Officer | Open Market Disposition | -31,492 | $6.42 |
| 2026-03-16 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -19,323 | $6.42 |
| 2026-02-01 | Sean McCarthy | Chairperson & CEO | Other Acquisition | +210,000 | -- |
| 2026-02-01 | Sean McCarthy | Chairperson & CEO | Other Derivative Acquisition | +980,000 | $6.09 |
| 2026-02-01 | Rachael Lester | Chief Business Officer & Senior VP | Other Acquisition | +20,000 | -- |
| 2026-02-01 | Rachael Lester | Chief Business Officer & Senior VP | Other Derivative Acquisition | +50,000 | $6.09 |
| 2026-02-01 | Yu-Waye Chu | Chief Medical Officer | Other Acquisition | +75,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
赛通姆治疗 讨论区 0 条评论